HYOSCINE BUTYLBROMIDE IN THE TREATMENT OF ABDOMINAL SPASMS


Cite item

Full Text

Abstract

Abdominal pain is one of the most common reasons why people seek medical care, and is often due to spasm of intra-abdominal visceral organs. Hyoscine butylbromide (HBB) is a quaternary ammonium compound which blocks the action of acetylcholine at parasympathetic sites (both muscarinic and nicotinic receptors) in smooth muscle, and in secretory glands. It causes decreased motility of the gastrointestinal tract and the urogenital tracts, and is useful in the treatment of spasms in these regions. Evidence exists to support its use in the management of non-specific colicky abdominal pain (in adults and children); irritable bowel syndrome; labor and delivery; dysmenorrhea; and to facilitate improved resolution in certain imaging techniques. Also HBB may be useful in injection form (not registered in the Russian Federation), in certain procedures, such as colonoscopy and sigmoidoscopy, and may be useful in the management of renal colic.

About the authors

L A Samuels

L A Samuels

References

  1. Quigley EM, Locke GR, Mueller-Lissner S, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther 2006;24(2):411-19.
  2. Weiser T, Just S. Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SH-SY5Y cells. Neurosci Lett 2009;6;450(3):258-61.
  3. Americo MF, Miranda JR, Cora LA, Romeiro FG. Electrical and mechanical effects of hyoscine butylbromide on the human stomach: a non-invasive approach. Physiol Meas 2009;30(4):363-70.
  4. Mueller-Lissner S, Tytgat GN, Paulo LG, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23(12):1741-48.
  5. Muller-Krampe B, Oberbaum M, Klein P, Weiser M. Effects of Spascupreel versus hyoscine butylbromide for gastrointestinal cramps in children. Pediatr Int 2007;49(3):328-34.
  6. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007;67(9):1343-57.
  7. Tytgat GN. Hyoscine butylbromide-a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr Med Res Opin 2008;24(11):3159-73.
  8. Schäfer E, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. Fortschr Med 1990;108(25):488-92.
  9. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004;10(28):3561-68.
  10. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15(3):355-61.
  11. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005;(2):CD003460.
  12. Kumar A, Deed JS, Bhasin B, Kumar A, Thomas S. Comparison of the effect of diclofenac with hyoscine-N-butylbromide in the symptomatic treatment of acute biliary colic. ANZ J Surg 2004;74(7):573-76.
  13. Ciccaglione AF, Grossi L, Cappello G, et al. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96(8):2306-11.
  14. Holdgate A, Oh CM. Is there a role for antimuscarinics in renal colic? A randomized controlled trial. J Urol 2005;174(2):572-75.
  15. Khalifa MS, Sharkawi MA. Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study. J Urol 1986;136(2):393-95.
  16. Al-Waili NS, Saloom KY. Intravenous tenoxicam to treat acute renal colic: comparison with buscopan compositum. J Pak Med Assoc 1998;48(12):370-72.
  17. Prcić A, Aganović D, Junuzović D, Kulovac B. Comparative efficiency study, safety and usage of tested drugs in patients with renal colic. Med Arch 2006;60(1):37-40.
  18. Mora Durban MJ, Extramiana Cameno J, Arrizabalaga Moreno M, Paniagua Andres P, Camp Herrero J, et al. Flubiprofen vs. dipyrone combined with hyoscine: the analgesic efficacy in renal colic. Arch Esp Urol 1995;48(9):867-73.
  19. Stankov G, Schmieder G, Zerle G, Schinzel S, Brune K. Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain. World J Urol 1994;12(3):155-61.
  20. de los Santos AR, Zmijanovich R, Perez Macri S, Marti ML, Di Girolamo G. Antispasmodic/analgesic associations in primary dysmenorrhea doubleblind crossover placebo-controlled clinical trial. Int J Clin Pharmacol Res 2001;21(1):21-9.
  21. Hernandez Bueno JA, de la Jara Diaz J, Sedeno Cruz F, Llorens Torres F. Analgesic-antispasmodic effect and safety of lysine clonixinate and L-hyoscinbutylbromide in the treatment of dysmenorrhea. Ginecol Obstet Mex 1998;66:35-9.
  22. Aggarwal P, Zutshi V, Batra S. Role of hyoscine N-butylbromide (HBB, buscopan (R)) as labor analgesic. Indian J Med Sci 2008;62(5):179-84.
  23. Sirohiwal D, Dahiya K, De M. Efficacy of hyoscine-N-butylbromide (Buscopan) suppositories as a cervical spasmolytic agent in labor. Aust N Z J Obstet Gynaecol 2005;45(2):128-29.
  24. Samuels LA, Christie L, Roberts-Gittens B, Fletcher H, Frederick J. The effect of hyoscine butylbromide on the first stage of labor in term pregnancies. BJOG 2007;114(12):1542-6.
  25. Tehalia Manpreet K, Sajjan Gouramba R, Korbu Jyothi, Venkatesh S, Biradar R. A comparative study of Hyoscine butylbromide versus Drotaverine hydrochloride in first stage of labor. J Obstet Gynecol India 2008;58(3):230-34.
  26. Gupta B, Nellore V, Mittal S. Drotaverine hydrochloride versus hyoscine-N-butylbromide in augmentation of labor. Int J Gynaecol Obstet 2008;100(3):244-47.
  27. Saunders BP, Elsby B, Boswell AM, Atkin W, Williams CB. Intravenous antispasmodic and patient-controlled analgesia are of benefit for screening flexible sigmoidoscopy. Gastrointest Endosc 1995;42(2):123-27.
  28. Yoshikawa I, Yamasaki M, Taguchi M, et al. Comparison of glucagon and scopolamine butylbromide as premedication for colonoscopy in unsedated patients. Dis Colon Rectum 2006;49(9):1393-98.
  29. Mui LM, Ng EK, Chan KC, et al. Randomized, double-blinded, placebocontrolled trial of intravenously administered hyoscine N-butylbromide in patients undergoing colonoscopy with patient-controlled sedation. Gastrointest Endosc 2004;59(1):22-7.
  30. Wagner M, Klessen C, Rief M, et al. High-resolution T2-weighted abdominal magnetic resonance imaging using respiratory triggering: impact of butylscopolamine on image quality. Acta Radiol 2008;49(4):376-82.
  31. Froehlich JM, Daenzer M, von Weymarn C, Erturk SM, Zollikofer CL, Patak MA. Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging. Eur Radiol 2009;4.
  32. Dyde R, Chapman AH, Gale R, Mackintosh A, Tolan DJ. Precautions to be taken by radiologists and radiographers when prescribing hyoscine-N-butylbromide. Clin Radiol 2008;63(7):739-43.
  33. Thomas L, Webb C, Duvvi S, Jones T, Reddy KT. Is buscopan effective in meat bolus obstruction? Clin Otolaryngol 2005;30(2):183-85.
  34. Basavaraj S, Penumetcha KR, Cable HR, Umapathy N. Buscopan in oesophageal food bolus: is it really effective? Eur Arch Otorhinolaryngol 2005;262(7):524-27.
  35. Negro S, Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2002;10(1):65-70.
  36. Barcia E, Reyes R, Luz Azuara M, Sanchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butylbromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003;11(2):107-13.
  37. Barcia E, Reyes R, Azuara ML, Sanchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-N-butylbromide. Support Care Cancer 2005;13(4):239-45.
  38. Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butylbromide combined in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients. Int J Pharm 2006 13;307(2):278-84.
  39. Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butylbromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007;15(1):57-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies